# Cystic Fibrosis Foundation

> Cystic Fibrosis Foundation is a VC fund backing Biotechnology and Health Care. See 69 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bethesda, United States
- Total investments: 69
- Last investment: Aug 2026
- Lead investor: 65%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/13317
- X (Twitter): https://twitter.com/CF_Foundation
- Website: https://www.cff.org/
- Facebook: https://www.facebook.com/cysticfibrosisfoundation

Cystic Fibrosis Foundation is a VC fund in Bethesda focused on Biotechnology and Health Care. The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment and ensuring access to high-quality, specialized care.

## Contacts

5 contacts available for Cystic Fibrosis Foundation. Shizune tracks 9 team members at Cystic Fibrosis Foundation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/the-cystic-fibrosis-foundation?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 39 | 57% |
| Health Care | 24 | 35% |
| Pharmaceutical | 20 | 29% |
| Therapeutics | 15 | 22% |
| Medical | 10 | 14% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 31 | 45% |
| Funding Round | 6 | 9% |
| Post-IPO Equity | 5 | 7% |
| Series A | 4 | 6% |
| Series B | 4 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 34 | 49% |
| United Kingdom | 5 | 7% |
| Canada | 3 | 4% |
| Israel | 2 | 3% |
| Denmark | 1 | 1% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Clancy JP | Vice President of Clinical Research at Cystic Fibrosis | 1 | — |
| Irena Barisic | Chief Operating and Financial Officer | 0 | — |
| Kathryn Brown | Chief Communications and Marketing Officer | 0 | — |
| Preston Campbell | Executive Vice President for Medical Affairs | 0 | — |
| Amber Walters | Development Director | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. |  | Venture - Series Unknown | Aug 06, 2026 |  |
| Splisense | Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried. | $13M |  | Jun 16, 2026 |  |
| 4D Molecular Therapeutics | 4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions. | $7.5M | Post-IPO Equity | Oct 13, 2025 |  |
| SNIPR Biome | SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target andkill bacteria with specific DNA sequences. | $40.9M | Series B | Aug 07, 2025 |  |
| Prime Medicine | Prime Medicine develops gene editing therapies based on Prime Editing, a technology that enables the precise correction of genetic mutations at their source. The company focuses on treating genetic diseases by repairing DNA without making double-strand breaks, offering an alternative to traditional CRISPR approaches. Prime Editing is designed totarget and correct a wide variety of mutations, allowing the development of therapeutic programs across multiple organ systems. Prime Medicine's pipeline includes investigational therapies for diseases affecting the liver, eye, blood, and central nervous system. The company integrates its proprietary delivery platforms and screening tools to enhance the specificity and durability of gene edits. Its research and development efforts aim to translate advances in genome editing into clinical applications with the potential for one-time, curative treatments. | $24M | Post-IPO Equity | Jul 16, 2025 |  |
| BIOMx | BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $12M | Post-IPO Equity | Feb 26, 2025 |  |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $15M | Venture - Series Unknown | Nov 18, 2024 |  |
| BIOMx | BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $50M | Post-IPO Equity | Mar 14, 2024 |  |
| Sionna Therapeutics | Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF). | $182M | Series C | Mar 06, 2024 |  |
| Prime Medicine | Prime Medicine develops gene editing therapies based on Prime Editing, a technology that enables the precise correction of genetic mutations at their source. The company focuses on treating genetic diseases by repairing DNA without making double-strand breaks, offering an alternative to traditional CRISPR approaches. Prime Editing is designed totarget and correct a wide variety of mutations, allowing the development of therapeutic programs across multiple organ systems. Prime Medicine's pipeline includes investigational therapies for diseases affecting the liver, eye, blood, and central nervous system. The company integrates its proprietary delivery platforms and screening tools to enhance the specificity and durability of gene edits. Its research and development efforts aim to translate advances in genome editing into clinical applications with the potential for one-time, curative treatments. | $15M |  | Jan 25, 2024 |  |

10 of 69 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together
- [The Rise Fund](https://shizune.co/investors/profile/the-rise-fund) — VC Fund, 4 deals together
- Deerfield Management — VC Fund, 3 deals together
- T. Rowe Price — VC Fund, 3 deals together
- [Aligo Innovation](https://shizune.co/investors/profile/aligo-innovation) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does Cystic Fibrosis Foundation invest in?

Cystic Fibrosis Foundation invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Grant and Funding Round stage. Most of the 69 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cystic Fibrosis Foundation?

Public channels for Cystic Fibrosis Foundation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cystic Fibrosis Foundation?

The team at Cystic Fibrosis Foundation includes Clancy JP (Vice President of Clinical Research at Cystic Fibrosis), Irena Barisic (Chief Operating and Financial Officer) and Kathryn Brown (Chief Communications and Marketing Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co